import { useMutation } from '@tanstack/react-query';

interface EnhancedAIRequest {
  question: string;
  sessionId?: string;
  context?: string;
}

interface EnhancedAIResponse {
  id: string;
  question: string;
  answer: string;
  sources: string[];
  citations?: Array<{
    source: string;
    content: string;
  }>;
  confidenceScore: number;
  sessionId?: string;
  agentUsed: boolean;
  createdAt: string;
}

// Mock enhanced responses for development
const mockEnhancedResponses: Record<string, string> = {
  'competitive': `**COMPETITIVE LANDSCAPE ANALYSIS**

**Market Position Assessment:**
Keytruda maintains market leadership in PD-1 inhibitors with ~42% market share, driven by first-mover advantage and broad indication coverage across 30+ tumor types.

**Key Competitive Threats:**
1. **Opdivo (Bristol Myers Squibb)** - Threat Level: HIGH (8/10)
   - Strong in combination therapies
   - 28% market share with focus on difficult-to-treat cancers
   - Pipeline advantage in hematologic malignancies

2. **Tecentriq (Genentech/Roche)** - Threat Level: MEDIUM (6/10)
   - 18% market share, growing in bladder cancer
   - Strong combination strategy with chemotherapy
   - Aggressive pricing in emerging markets

**Strategic Implications:**
- Patent cliff approaching 2028-2030 creates urgency for lifecycle management
- Biosimilar competition expected to intensify post-2030
- Combination therapy differentiation becoming critical

**Quantitative Insights:**
- Market growing at 12% CAGR through 2028
- Combination therapies represent 65% of new approvals
- First-line indications drive 78% of revenue

**Recommended Actions:**
1. Accelerate combination development programs
2. Strengthen real-world evidence generation
3. Expand into earlier treatment settings
4. Monitor Opdivo's LAG-3 combination closely`,

  'clinical': `**CLINICAL TRIAL COMPETITIVE INTELLIGENCE**

**Pipeline Threat Assessment:**
Current analysis of 2,847 active oncology immunotherapy trials reveals significant competitive activity.

**High-Priority Competitive Threats:**

**Phase III Trials (Immediate Threat):**
1. **Competitor X + Chemotherapy** (NCT04567890)
   - First-line NSCLC, n=600 patients
   - Primary endpoint: Overall Survival
   - Estimated completion: Q2 2025
   - **Threat Level: CRITICAL** - Direct head-to-head positioning

2. **Novel PD-L1 Inhibitor** (NCT04123456)
   - Triple-negative breast cancer
   - Breakthrough therapy designation granted
   - **Threat Level: HIGH** - New indication expansion

**Pipeline Momentum Analysis:**
- Competitors have 23% more Phase III trials in key indications
- Novel targets (LAG-3, TIGIT) showing promising early data
- Combination strategies dominating 67% of new trials

**Timeline Risk Assessment:**
- 3 competitive approvals expected in next 18 months
- 2 potential label expansions could impact market share by 15-20%
- Biosimilar filings anticipated starting 2026

**Strategic Recommendations:**
1. **Immediate:** File additional combination studies in high-value indications
2. **6 months:** Strengthen biomarker strategy for patient selection
3. **12 months:** Consider strategic partnerships for novel combinations`,

  'regulatory': `**REGULATORY IMPACT ANALYSIS**

**Recent FDA Actions (Last 90 Days):**

**Critical Approvals:**
1. **Competitor PD-1 Inhibitor** - Approved for adjuvant melanoma
   - **Market Impact:** Direct competition in $2.3B indication
   - **Response Required:** Within 30 days - update competitive positioning

2. **CAR-T Therapy Expansion** - New indication in lymphoma
   - **Market Impact:** Potential 15% share erosion in hematologic cancers
   - **Strategic Implication:** Accelerate cellular therapy partnerships

**Safety Signals:**
- 3 new black box warnings for checkpoint inhibitors
- Increased focus on immune-related adverse events
- Enhanced pharmacovigilance requirements

**Regulatory Trends:**
- FDA prioritizing combination approvals (67% of recent approvals)
- Accelerated approval pathway usage increasing
- Real-world evidence requirements expanding

**Patent Landscape:**
- 2 key competitor patents expire 2025-2026
- Generic entry barriers weakening
- Formulation patents becoming critical

**Risk Assessment:**
- **High Risk:** Patent cliff exposure 2028-2030
- **Medium Risk:** New safety requirements increasing costs
- **Low Risk:** Regulatory pathway changes

**Recommended Actions:**
1. **Immediate:** File lifecycle management applications
2. **Q2 2024:** Strengthen safety database and REMS programs
3. **Q3 2024:** Evaluate biosimilar defense strategies`,

  'strategic': `**STRATEGIC MARKET INTELLIGENCE**

**Market Opportunity Analysis:**

**Emerging High-Value Opportunities:**
1. **Adjuvant Therapy Market** - $8.2B by 2028
   - Early-stage treatment settings showing 45% growth
   - Competitive advantage through biomarker-driven approaches
   - **Investment Priority: HIGH**

2. **Combination Therapy Expansion** - $15.6B opportunity
   - Novel targets (LAG-3, TIGIT) creating differentiation
   - Pricing premium sustainable through 2030
   - **Investment Priority: CRITICAL**

**Competitive Response Analysis:**
Recent launch impact assessment shows:
- Market share stable at 42% despite new entrants
- Premium pricing maintained in key indications
- Combination strategies driving growth

**M&A Activity Impact:**
- 3 major acquisitions in immunotherapy space (last 12 months)
- Consolidation creating stronger competitive threats
- Novel technology platforms being integrated

**Investment Priorities (Next 24 Months):**
1. **$2.1B** - Combination development programs
2. **$800M** - Real-world evidence generation
3. **$500M** - Manufacturing capacity expansion
4. **$300M** - Digital health partnerships

**Competitive Advantage Sustainability:**
- **Strengths:** Broad indication portfolio, manufacturing scale
- **Vulnerabilities:** Patent expiration, biosimilar competition
- **Opportunities:** Emerging markets, novel combinations
- **Threats:** Regulatory changes, pricing pressure

**Strategic Recommendations:**
1. **Accelerate** combination therapy development (18-month timeline)
2. **Expand** into emerging markets with local partnerships
3. **Invest** in next-generation manufacturing capabilities
4. **Develop** comprehensive biosimilar defense strategy`,

  'default': `**PHARMACEUTICAL COMPETITIVE INTELLIGENCE ANALYSIS**

Based on current market data and competitive intelligence, here are the key insights:

**Market Overview:**
The pharmaceutical competitive landscape continues to evolve rapidly, with increasing focus on precision medicine, combination therapies, and real-world evidence generation.

**Key Trends:**
- Accelerated regulatory pathways becoming standard
- Combination therapy strategies dominating pipelines
- Real-world evidence requirements expanding
- Biosimilar competition intensifying

**Strategic Considerations:**
1. **Innovation Focus:** Novel targets and combination approaches
2. **Market Access:** Value-based pricing and outcomes data
3. **Competitive Intelligence:** Enhanced monitoring and response capabilities
4. **Lifecycle Management:** Patent cliff mitigation strategies

**Data Sources:** Pharmaceutical Intelligence Database, Clinical Trials Registry, FDA Database, Patent Analytics

**Confidence Level:** 85% - Based on comprehensive data analysis and market intelligence`
};

export const useEnhancedAI = () => {
  return useMutation({
    mutationFn: async (request: EnhancedAIRequest): Promise<{ data: EnhancedAIResponse }> => {
      // Simulate enhanced AI processing time
      await new Promise(resolve => setTimeout(resolve, 2000));
      
      // Determine response type based on question content
      const question = request.question.toLowerCase();
      let responseKey = 'default';
      let analysisType = 'General Analysis';
      
      if (question.includes('competitive') || question.includes('competitor') || question.includes('landscape')) {
        responseKey = 'competitive';
        analysisType = 'Competitive Analysis';
      } else if (question.includes('trial') || question.includes('clinical') || question.includes('phase')) {
        responseKey = 'clinical';
        analysisType = 'Clinical Intelligence';
      } else if (question.includes('fda') || question.includes('regulatory') || question.includes('approval')) {
        responseKey = 'regulatory';
        analysisType = 'Regulatory Intelligence';
      } else if (question.includes('market') || question.includes('strategy') || question.includes('opportunity')) {
        responseKey = 'strategic';
        analysisType = 'Strategic Intelligence';
      }
      
      const response: EnhancedAIResponse = {
        id: `enhanced-insight-${Date.now()}`,
        question: request.question,
        answer: mockEnhancedResponses[responseKey],
        sources: [
          'CI Analysis Agent',
          'Pharmaceutical Intelligence Database',
          'ClinicalTrials.gov',
          'FDA Database',
          'Patent Analytics Platform',
          'Market Research Database'
        ],
        citations: [
          {
            source: 'Market Research Database',
            content: 'Current market share data shows PD-1 inhibitor segment growing at 12% CAGR with Keytruda maintaining leadership position...'
          },
          {
            source: 'ClinicalTrials.gov',
            content: 'Analysis of 2,847 active oncology immunotherapy trials reveals significant competitive activity in combination therapies...'
          },
          {
            source: 'FDA Database',
            content: 'Recent regulatory approvals indicate accelerated pathway usage increasing, with 67% of approvals involving combinations...'
          }
        ],
        confidenceScore: Math.floor(Math.random() * 15) + 85, // 85-100%
        sessionId: request.sessionId,
        agentUsed: true, // Simulate agent usage
        createdAt: new Date().toISOString()
      };
      
      return { data: response };
    },
  });
};